Opioids Drugs Market is estimated to increase at a Compounded Annual Growth Rate of 3.4% CAGR over the forecast period from 2024 to 2030
The Opioids Drugs Market study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments- By Product (Codeine, Fentanyl, Morphine, Meperidine, Methadone, Others), By Receptor Binding, Strong Agonist, Mild to Moderate Agonist), By Application (Pain Management, Cold and Cough, Diarrhoea, Others).
An Introduction to Opioids Drugs Market in 2024
In 2024, the market for opioids drugs continues to be a subject of scrutiny and innovation, given the ongoing opioid crisis and the need for effective pain management strategies with reduced risk of addiction and misuse. Opioids are a class of potent analgesic medications used to alleviate moderate to severe pain, including acute pain following surgery or injury, chronic pain conditions, and cancer-related pain. Common opioids include morphine, oxycodone, hydrocodone, fentanyl, and tramadol, which act on opioid receptors in the central nervous system to modulate pain perception and transmission. Technological advancements in opioid formulations include the development of abuse-deterrent formulations, extended-release formulations, and combination products with non-opioid analgesics for providing sustained pain relief while minimizing the risk of abuse, overdose, and diversion. Moreover, the integration of prescription drug monitoring programs (PDMPs), opioid risk assessment tools, and evidence-based pain management guidelines enhances opioid prescribing practices, patient monitoring, and identification of at-risk individuals for opioid misuse or addiction. With the increasing emphasis on opioid stewardship, multimodal analgesia, and non-pharmacological pain management approaches, the market for opioids drugs is undergoing transformation, with a focus on balancing the benefits of pain relief with the risks of opioid-related harms, addiction, and public health consequences. Continued research, regulatory efforts, and innovation in opioid therapeutics aim to improve pain management outcomes and mitigate the societal impact of the opioid epidemic.
Market Trend: Increased Focus on Alternative Pain Management Therapies
A prominent trend in the opioids drugs market is the increased focus on alternative pain management therapies, driven by concerns over opioid misuse, addiction, and adverse effects. Healthcare providers, policymakers, and patients are increasingly seeking non-opioid treatment options for pain management, including nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen, physical therapy, acupuncture, and cognitive-behavioral therapy. This trend is fueled by the opioid epidemic, regulatory initiatives to restrict opioid prescribing, and public health campaigns to raise awareness about the risks associated with long-term opioid use. Additionally, advancements in pain management techniques, such as nerve blocks, spinal cord stimulation, and regenerative medicine approaches, offer alternative strategies for managing acute and chronic pain without the need for opioid medications. As healthcare systems prioritize safer, more effective pain management approaches, the market for opioids drugs is expected to witness a shift towards non-opioid therapies and multimodal pain management strategies.
Market Driver: Rising Incidence of Chronic Pain Conditions
The primary driver propelling the opioids drugs market is the rising incidence of chronic pain conditions, such as osteoarthritis, low back pain, neuropathic pain, and cancer-related pain, driving the demand for analgesic medications to alleviate symptoms and improve patient quality of life. Chronic pain affects millions of individuals worldwide, contributing to disability, decreased productivity, and impaired quality of life. Opioid medications, such as oxycodone, hydrocodone, and morphine, are commonly prescribed for moderate to severe pain management, particularly in patients with cancer, postoperative pain, and terminal illnesses. This driver is supported by demographic aging, increasing prevalence of chronic diseases, and advances in medical treatments that prolong survival but may also lead to long-term pain management needs. Additionally, expanding access to healthcare services, rising healthcare expenditures, and growing awareness of pain management options contribute to the growing demand for opioids drugs. As healthcare providers strive to address the complex needs of patients with chronic pain, the market for opioids drugs is expected to experience sustained growth and demand, driven by the imperative to improve pain control and enhance patient comfort and function.
Market Opportunity: Development of Abuse-deterrent Formulations and Novel Analgesics
An opportunity within the opioids drugs market lies in the development of abuse-deterrent formulations and novel analgesics that offer improved safety, efficacy, and abuse mitigation features compared to traditional opioid medications. Opportunities exist for pharmaceutical companies and biotechnology firms to innovate formulations that deter tampering, manipulation, and misuse of opioid drugs, such as extended-release formulations with physical and chemical barriers to prevent crushing, chewing, or extraction of the active ingredient. This opportunity is driven by regulatory incentives, public health initiatives, and payer reimbursement policies that incentivize the development and adoption of abuse-deterrent opioids to reduce the risk of diversion, addiction, and overdose. Additionally, the discovery and development of novel analgesic agents, such as kappa opioid receptor agonists, cannabinoid receptor modulators, and non-opioid receptor targets, offer opportunities to expand the armamentarium of pain management therapies with safer and more effective alternatives to traditional opioids. Collaborations between industry stakeholders, academic researchers, and government agencies can accelerate the translation of innovative concepts into clinically validated products, providing patients with advanced pain relief options while mitigating the risks associated with opioid use. As healthcare systems strive to address the opioid epidemic and improve pain management practices, the development of abuse-deterrent formulations and novel analgesics presents opportunities for differentiation, market expansion, and leadership in delivering safer, more effective pain management solutions for patients with chronic pain conditions.
Opioids Drugs Market Share Analysis: Fentanyl
Among the various opioids drugs, Fentanyl stands out as experiencing rapid growth in the opioids drugs market. Fentanyl is a potent synthetic opioid that is significantly stronger than morphine and other traditional opioids. Its high potency and rapid onset of action make it a valuable option for managing severe pain, particularly in cases where other opioids may be insufficient. Fentanyl's versatility extends beyond pain management; it is also used in anesthesia and as an adjunct to general anesthesia. Additionally, fentanyl's various formulations, including transdermal patches, lozenges, and injectable formulations, provide healthcare providers with flexibility in administering the drug to patients. With the increasing prevalence of chronic pain conditions and the growing demand for effective pain management solutions, the market for fentanyl is expected to continue expanding rapidly. Furthermore, ongoing research and development efforts aimed at enhancing the safety and efficacy of fentanyl formulations are to further drive its growth in the opioids drugs market.
Opioids Drugs Competitive Analysis
The market research study provides in-depth insights into leading companies including the SWOT analyses, product profile, financial details, and recent developments acrossAbbvie Inc (Allergan), AcelRx Pharmaceuticals Inc, Alcaliber SA, Amneal Pharmaceuticals Inc, Endo Pharmaceuticals Inc, Hikma Pharmaceuticals PLC, Johnson and Johnson, Mallinckrodt Pharmaceuticals LLC, Pfizer Inc, Purdue Pharmaceuticals L.P., Sun Pharmaceutical Industries Ltd, Teva Pharmaceuticals Inc, Vertice Pharma LLC, Zyla Life Sciences
Opioids Drugs Market Segmentation
By Product
Codeine
Fentanyl
Morphine
Meperidine
Methadone
Others
By Receptor Binding
Strong Agonist
Mild to Moderate Agonist
By Application
Pain Management
Cold and Cough
Diarrhoea
Others
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)
Opioids Drugs Market Companies
Abbvie Inc (Allergan)
AcelRx Pharmaceuticals Inc
Alcaliber SA
Amneal Pharmaceuticals Inc
Endo Pharmaceuticals Inc
Hikma Pharmaceuticals PLC
Johnson and Johnson
Mallinckrodt Pharmaceuticals LLC
Pfizer Inc
Purdue Pharmaceuticals L.P.
Sun Pharmaceutical Industries Ltd
Teva Pharmaceuticals Inc
Vertice Pharma LLC
Zyla Life Sciences
Reasons to Buy the Opioids Drugs Market Study
• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Opioids Drugs Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Opioids Drugs Market industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.
TABLE OF CONTENTS
1 Introduction to 2024 Opioids Drugs Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Covered
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain
2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations
3 Executive Summary
3.1 Global Opioids Drugs Market Size Outlook, $ Million, 2021 to 2030
3.2 Opioids Drugs Market Outlook by Type, $ Million, 2021 to 2030
3.3 Opioids Drugs Market Outlook by Product, $ Million, 2021 to 2030
3.4 Opioids Drugs Market Outlook by Application, $ Million, 2021 to 2030
3.5 Opioids Drugs Market Outlook by Key Countries, $ Million, 2021 to 2030
4 Market Dynamics
4.1 Key Driving Forces of Opioids Drugs Industry
4.2 Key Market Trends in Opioids Drugs Industry
4.3 Potential Opportunities in Opioids Drugs Industry
4.4 Key Challenges in Opioids Drugs Industry
5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global Opioids Drugs Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook
6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts
7 Global Opioids Drugs Market Outlook by Segments
7.1 Opioids Drugs Market Outlook by Segments, $ Million, 2021- 2030
By Product
Codeine
Fentanyl
Morphine
Meperidine
Methadone
Others
By Receptor Binding
Strong Agonist
Mild to Moderate Agonist
By Application
Pain Management
Cold and Cough
Diarrhoea
Others
8 North America Opioids Drugs Market Analysis and Outlook To 2030
8.1 Introduction to North America Opioids Drugs Markets in 2024
8.2 North America Opioids Drugs Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Opioids Drugs Market size Outlook by Segments, 2021-2030
By Product
Codeine
Fentanyl
Morphine
Meperidine
Methadone
Others
By Receptor Binding
Strong Agonist
Mild to Moderate Agonist
By Application
Pain Management
Cold and Cough
Diarrhoea
Others
9 Europe Opioids Drugs Market Analysis and Outlook To 2030
9.1 Introduction to Europe Opioids Drugs Markets in 2024
9.2 Europe Opioids Drugs Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Opioids Drugs Market Size Outlook by Segments, 2021-2030
By Product
Codeine
Fentanyl
Morphine
Meperidine
Methadone
Others
By Receptor Binding
Strong Agonist
Mild to Moderate Agonist
By Application
Pain Management
Cold and Cough
Diarrhoea
Others
10 Asia Pacific Opioids Drugs Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific Opioids Drugs Markets in 2024
10.2 Asia Pacific Opioids Drugs Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Opioids Drugs Market size Outlook by Segments, 2021-2030
By Product
Codeine
Fentanyl
Morphine
Meperidine
Methadone
Others
By Receptor Binding
Strong Agonist
Mild to Moderate Agonist
By Application
Pain Management
Cold and Cough
Diarrhoea
Others
11 South America Opioids Drugs Market Analysis and Outlook To 2030
11.1 Introduction to South America Opioids Drugs Markets in 2024
11.2 South America Opioids Drugs Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Opioids Drugs Market size Outlook by Segments, 2021-2030
By Product
Codeine
Fentanyl
Morphine
Meperidine
Methadone
Others
By Receptor Binding
Strong Agonist
Mild to Moderate Agonist
By Application
Pain Management
Cold and Cough
Diarrhoea
Others
12 Middle East and Africa Opioids Drugs Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa Opioids Drugs Markets in 2024
12.2 Middle East and Africa Opioids Drugs Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Opioids Drugs Market size Outlook by Segments, 2021-2030
By Product
Codeine
Fentanyl
Morphine
Meperidine
Methadone
Others
By Receptor Binding
Strong Agonist
Mild to Moderate Agonist
By Application
Pain Management
Cold and Cough
Diarrhoea
Others
13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
Abbvie Inc (Allergan)
AcelRx Pharmaceuticals Inc
Alcaliber SA
Amneal Pharmaceuticals Inc
Endo Pharmaceuticals Inc
Hikma Pharmaceuticals PLC
Johnson and Johnson
Mallinckrodt Pharmaceuticals LLC
Pfizer Inc
Purdue Pharmaceuticals L.P.
Sun Pharmaceutical Industries Ltd
Teva Pharmaceuticals Inc
Vertice Pharma LLC
Zyla Life Sciences
14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise
By Product
Codeine
Fentanyl
Morphine
Meperidine
Methadone
Others
By Receptor Binding
Strong Agonist
Mild to Moderate Agonist
By Application
Pain Management
Cold and Cough
Diarrhoea
Others
Countries Analyzed
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)
